Presence of lysine at aa 335 of the hemagglutinin-neuraminidase protein of mumps virus vaccine strain Urabe AM9 is not a requirement for neurovirulence

Vaccine

Volumn 27, Issue 42, 2009, Pages 5822-5829

  Sauder, Christian J ^a   Zhang, Cheryl X ^a   Link, Malen A ^a   Duprex, W Paul ^b   Carbone, Kathryn M ^c   Rubin, Steven A ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Mumps virus; Neurovirulence; Urabe AM9 vaccine

Indexed keywords

GLUTAMIC ACID; LYSINE; MUMPS VACCINE; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

AMINO ACID COMPOSITION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUMPS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; VIRAL GENETICS; VIROGENESIS; VIRUS ATTENUATION; VIRUS STRAIN; VIRUS VIRULENCE;

AMINO ACID SUBSTITUTION; ANIMALS; CERCOPITHECUS AETHIOPS; DNA, COMPLEMENTARY; HN PROTEIN; HUMANS; LYSINE; MUMPS VACCINE; MUMPS VIRUS; MUTATION; RATS; RATS, INBRED LEW; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VACCINES, ATTENUATED; VERO CELLS; VIRULENCE; VIRUS REPLICATION;

EID: 69749119475     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.051     Document Type: Article

References (42)

1. Gotoh B., Komatsu T., Takeuchi K., and Yokoo J. Paramyxovirus strategies for evading the interferon response. Rev Med Virol 12 6 (2002) 337-357
2. Paterson R.G., and Lamb R.A. RNA editing by G-nucleotide insertion in mumps virus P-gene mRNA transcripts. J Virol 64 9 (1990) 4137-4145
3. Elliott G.D., Yeo R.P., Afzal M.A., Simpson E.J., Curran J.A., and Rima B.K. Strain-variable editing during transcription of the P gene of mumps virus may lead to the generation of non-structural proteins NS1 (V) and NS2. J Gen Virol 71 Pt 7 (1990) 1555-1560
4. Takimoto T., and Portner A. Molecular mechanism of paramyxovirus budding. Virus Res 106 2 (2004) 133-145
5. Wilson R.L., Fuentes S.M., Wang P., Taddeo E.C., Klatt A., Henderson A.J., et al. Function of small hydrophobic proteins of paramyxovirus. J Virol 80 4 (2006) 1700-1709
6. Hviid A., Rubin S., and Mühlemann K. Mumps Lancet 371 9616 (2008) 932-944
7. Plotkin S.A., and Rubin S.A. Mumps vaccine. In: Plotkin S.A. (Ed). Vaccines. 5th ed. (2008), Saunders Elsevier, Philadelphia 435-465
8. Dayan G.H., and Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks?. Clin Infect Dis 47 11 (2008) 1458-1467
9. Marin M., Quinlisk P., Shimabukuro T., Sawhney C., Brown C., and Lebaron C.W. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students-Iowa, 2006. Vaccine 26 29-30 (2008) 3601-3607
10. Gupta R.K., Best J., and MacMahon E. Mumps and the UK epidemic 2005. BMJ 330 7500 (2005) 1132-1135
11. Bonnet M.C., Dutta A., Weinberger C., and Plotkin S.A. Mumps vaccine virus strains and aseptic meningitis. Vaccine 24 49-50 (2006) 7037-7045
12. Hashimoto H., Fujioka M., and Kinumaki H. An office-based prospective study of deafness in mumps. Pediatr Infect Dis J 28 3 (2009) 173-175
13. Rubin S.A., Snoy P., Wright K.E., Brown E.G., Reeve P., Beeler J.A., et al. The mumps virus neurovirulence safety test in rhesus monkeys: a comparison of mumps virus strains. J Infect Dis 180 2 (1999) 521-525
14. Malik T., Sauder C., Wolbert C., Zhang C., Carbone K.M., and Rubin S. A single nucleotide change in the mumps virus F gene affects virus fusogenicity in vitro and virulence in vivo. J Neurovirol 13 6 (2007) 513-521
15. Malik T.H., Wolbert C., Nerret L., Sauder C., and Rubin S. Single amino acid changes in the mumps virus HN and L proteins are associated with neuroattenuation. J Gen Virol 90 Pt 7 (2009) 1741-1747
16. Lemon K., Rima B.K., McQuaid S., Allen I.V., and Duprex W.P. The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence. J Virol 81 15 (2007) 8293-8302
17. Shah D., Vidal S., Link M.A., Rubin S.A., and Wright K.E. Identification of genetic mutations associated with attenuation and changes in tropism of Urabe mumps virus. J Med Virol 81 1 (2009) 130-138
18. Brown E.G., Dimock K., and Wright K.E. The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease. J Infect Dis 174 (1996) 619-622
19. Afzal M.A., Yates P.J., and Minor P.D. Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps Urabe vaccine strain. J Infect Dis 177 (1998) 265-266
20. Wright K.E., Dimock K., and Brown E.G. Biological characteristics of genetic variants of Urabe AM9 mumps vaccine virus. Virus Res 67 1 (2000) 49-57
21. Cusi M.G., Santini L., Bianchi S., Valassina M., and Valensin P.E. Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in wild-type strains of mumps virus is the most relevant marker of virulence. J Clin Microbiol 36 12 (1998) 3743-3744
22. Amexis G., Fineschi N., and Chumakov K. Correlation of genetic variability with safety of mumps vaccine Urabe AM9 strain. Virology 287 1 (2001) 234-241
23. Mori C., Tooriyama T., Imagawa T., and Yamanishi K. Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in the mumps virus Urabe vaccine strain. J Infect Dis 175 6 (1997) 1548-1549
24. Sauder C.J., Vandenburgh K.M., Iskow R.C., Malik T., Carbone K.M., and Rubin S.A. Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity. Virology 350 1 (2006) 48-57
25. Reyes-Leyva J., Banos R., Borraz-Argüello M., Santos-López G., Rosas N., Alvarado G., et al. Amino acid change 335 E to K affects the sialic-acid-binding and neuraminidase activities of Urabe AM9 mumps virus hemagglutinin-neuraminidase glycoprotein. Microbes Infect 9 2 (2007) 234-240
26. Rubin S.A., Pletnikov M., Taffs R., Snoy P.J., Kobasa D., Brown E.G., et al. Evaluation of a neonatal rat model for prediction of mumps virus neurovirulence in humans. J Virol 74 11 (2000) 5382-5384
27. Rubin S.A., Afzal M.A., Powell C.L., Bentley M.L., Auda G.R., Taffs R.E., et al. The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study. J Infect Dis 191 7 (2005) 1123-1128
28. Buchholz U.J., Finke S., and Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73 1 (1999) 251-259
29. Clarke D.K., Sidhu M.S., Johnson J.E., and Udem S.A. Rescue of mumps virus from cDNA. J Virol 74 10 (2000) 4831-4838
30. Moss B., Elroy-Stein O., Mizukami T., Alexander W.A., and Fuerst T.R. Product review. New mammalian expression vectors. Nature 348 6296 (1990) 91-92
31. Santos-López G., Cruz C., Pazos N., Vallejo V., Reyes-Leyva J., and Tapia-Ramirez J. Two clones obtained from Urabe AM9 mumps virus vaccine differ in their replicative efficiency in neuroblastoma cells. Microbes Infect 8 2 (2006) 332-339
32. Sidhu M.S., Menonna J.P., Cook S.D., Dowling P.C., and Udem S.A. Canine distemper virus L gene: sequence and comparison with related viruses. Virology 193 1 (1993) 50-65
33. Takeuchi K., Tanabayashi K., Hishiyama M., Yamada A., and Sugiura A. Variations of nucleotide sequences and transcription of the SH gene among mumps virus strains. Virology 181 1 (1991) 364-366
34. Takeuchi K., Tanabayashi K., Hishiyama M., and Yamada A. The mumps virus SH protein is a membrane protein and not essential for virus growth. Virology 225 1 (1996) 156-162
35. Rassa J.C., Wilson G.M., Brewer G.A., and Parks G.D. Spacing constraints on reinitiation of paramyxovirus transcription: the gene end U tract acts as a spacer to separate gene end from gene start sites. Virology 274 2 (2000) 438-449
36. Hinzman E.E., Barr J.N., and Wertz G.W. Identification of an upstream sequence element required for vesicular stomatitis virus mRNA transcription. J Virol 76 15 (2002) 7632-7641
37. Kolakofsky D., Roux L., Garcin D., and Ruigrok R.W. Paramyxovirus mRNA editing, the "rule of six" and error catastrophe: a hypothesis. J Gen Virol 86 Pt 7 (2005) 1869-1877
38. Skiadopoulos M.H., Vogel L., Riggs J.M., Surman S.R., Collins P.L., and Murphy B.R. The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations. J Virol 77 1 (2003) 270-279
39. Biacchesi S., Murphy B.R., Collins P.L., and Buchholz U.J. Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro. J Virol 81 11 (2007) 6057-6067
40. Horton R.M. PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes. Mol Biotechnol 3 2 (1995) 93-99
41. Moeller-Ehrlich K., Ludlow M., Beschorner R., Meyermann R., Rima B.K., Duprex W.P., et al. Two functionally linked amino acids in the stem 2 region of measles virus haemagglutinin determine infectivity and virulence in the rodent central nervous system. J Gen Virol 88 (2007) 3112-3120
42. Arroyo J., Guirakhoo F., Fenner S., Zhang Z.X., Monath T.P., and Chambers T.J. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 75 2 (2001) 934-942